Results 191 to 200 of about 6,960 (260)

Short Inter‐Treatment Interval Treatment With Artificial Liver Support System Reduces 90‐Day Transplant‐Free Mortality in Patients With Hepatitis B Virus–Related Acute‐On‐Chronic Liver Failure: A Retrospective Observational Study

open access: yesArtificial Organs, EarlyView.
ALSS short inter‐treatment interval treatment (patients received two ALSS treatments within 48 h) correlates with improved liver function and 90‐day transplant‐free survival of HBV‐ACLF. This result provides a certain theoretical basis for the timing and time interval of ALSS for HBV‐ACLF, enriches the models and contents of ALSS treatment for HBV‐ACLF,
Jingjie Fu   +4 more
wiley   +1 more source

Adult‐onset Coats disease: A systematic review and meta‐analysis of imaging biomarkers and targeted therapies

open access: yesActa Ophthalmologica, EarlyView.
Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco   +2 more
wiley   +1 more source

Paediatric Index of Mortality 3 in Sweden: Validation and Recalibration to Improve Mortality Prediction in Paediatric Intensive Care

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim In Sweden, critically ill children are admitted to one of four dedicated paediatric intensive care units (PICUs) or general intensive care units (ICUs), reflecting a partly centralised system. The Paediatric Index of Mortality 3 (PIM3) is a widely used risk stratification tool for predicting mortality in critically ill children. This study
Lars Engerström   +4 more
wiley   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

open access: yesBritish Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê   +3 more
wiley   +1 more source

Long‐term outcomes for mechanical failure and revision following primary gender‐affirming penile prosthesis insertion

open access: yesBJU International, EarlyView.
Objectives To evaluate revision surgery for mechanical failure and overall revision rates of inflatable penile prostheses (IPPs) in assigned female‐at‐birth (AFAB) individuals. Patients and Methods This was a retrospective cohort study of all AFAB patients who underwent primary IPP implantation between September 2001 and July 2024.
Wai Gin Lee   +6 more
wiley   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

open access: yesBrain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira   +19 more
wiley   +1 more source

Diltiazem N‐oxide, a novel ischaemia‐activated prodrug, prevents ischaemia‐induced ventricular fibrillation without off‐target adverse effects

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy